Xiangxue Pharmaceutical Co.,Ltd. (300147.SZ)
CNY 6.02
(-1.95%)
CNY 6.02
(-1.95%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 2.29 Billion CNY | 5.13% |
| 2022 | 2.18 Billion CNY | -26.38% |
| 2021 | 2.97 Billion CNY | -3.3% |
| 2020 | 3.07 Billion CNY | 10.26% |
| 2019 | 2.78 Billion CNY | 11.26% |
| 2018 | 2.5 Billion CNY | 14.49% |
| 2017 | 2.18 Billion CNY | 17.47% |
| 2016 | 1.86 Billion CNY | 27.14% |
| 2015 | 1.46 Billion CNY | -3.9% |
| 2014 | 1.52 Billion CNY | 20.84% |
| 2013 | 1.26 Billion CNY | 57.44% |
| 2012 | 801.02 Million CNY | 30.02% |
| 2011 | 616.09 Million CNY | 20.01% |
| 2010 | 513.38 Million CNY | 35.59% |
| 2009 | 378.63 Million CNY | 28.43% |
| 2008 | 294.8 Million CNY | 14.13% |
| 2007 | 258.3 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 527.68 Million CNY | -7.24% |
| 2024 Q1 | 568.85 Million CNY | -0.39% |
| 2024 Q3 | 437.01 Million CNY | -17.18% |
| 2023 Q4 | 571.1 Million CNY | 8.4% |
| 2023 Q2 | 612.62 Million CNY | 4.06% |
| 2023 Q3 | 526.82 Million CNY | -14.01% |
| 2023 FY | 2.29 Billion CNY | 5.13% |
| 2023 Q1 | 588.72 Million CNY | 33.36% |
| 2022 Q4 | 441.46 Million CNY | -20.4% |
| 2022 FY | 2.18 Billion CNY | -26.38% |
| 2022 Q1 | 613.71 Million CNY | -16.4% |
| 2022 Q3 | 554.61 Million CNY | -3.92% |
| 2022 Q2 | 577.26 Million CNY | -5.94% |
| 2021 FY | 2.97 Billion CNY | -3.3% |
| 2021 Q4 | 734.12 Million CNY | 4.73% |
| 2021 Q1 | 790.92 Million CNY | 36.93% |
| 2021 Q2 | 744.58 Million CNY | -5.86% |
| 2021 Q3 | 700.94 Million CNY | -5.86% |
| 2020 Q2 | 1.01 Billion CNY | 27.67% |
| 2020 Q1 | 797.83 Million CNY | -0.64% |
| 2020 Q4 | 577.62 Million CNY | -14.8% |
| 2020 FY | 3.07 Billion CNY | 10.26% |
| 2020 Q3 | 678 Million CNY | -33.44% |
| 2019 Q2 | 671.83 Million CNY | 2.89% |
| 2019 Q1 | 652.95 Million CNY | -1.11% |
| 2019 FY | 2.78 Billion CNY | 11.26% |
| 2019 Q4 | 803 Million CNY | 21.96% |
| 2019 Q3 | 658.4 Million CNY | -2.0% |
| 2018 Q1 | 586.07 Million CNY | 5.47% |
| 2018 FY | 2.5 Billion CNY | 14.49% |
| 2018 Q2 | 647.12 Million CNY | 10.42% |
| 2018 Q3 | 610.74 Million CNY | -5.62% |
| 2018 Q4 | 660.3 Million CNY | 8.11% |
| 2017 Q4 | 555.68 Million CNY | 8.07% |
| 2017 Q1 | 481.85 Million CNY | -9.95% |
| 2017 FY | 2.18 Billion CNY | 17.47% |
| 2017 Q2 | 635.59 Million CNY | 31.91% |
| 2017 Q3 | 514.17 Million CNY | -19.1% |
| 2016 Q3 | 512.67 Million CNY | 6.11% |
| 2016 Q2 | 483.13 Million CNY | 45.88% |
| 2016 Q1 | 331.18 Million CNY | -11.2% |
| 2016 FY | 1.86 Billion CNY | 27.14% |
| 2016 Q4 | 535.08 Million CNY | 4.37% |
| 2015 Q4 | 372.94 Million CNY | 9.86% |
| 2015 Q3 | 339.48 Million CNY | -9.43% |
| 2015 Q1 | 377.36 Million CNY | -0.33% |
| 2015 Q2 | 374.81 Million CNY | -0.68% |
| 2015 FY | 1.46 Billion CNY | -3.9% |
| 2014 Q3 | 398.95 Million CNY | 2.09% |
| 2014 FY | 1.52 Billion CNY | 20.84% |
| 2014 Q4 | 378.62 Million CNY | -5.1% |
| 2014 Q2 | 390.79 Million CNY | 9.9% |
| 2014 Q1 | 355.6 Million CNY | -22.07% |
| 2013 Q3 | 351.52 Million CNY | 43.62% |
| 2013 Q4 | 456.28 Million CNY | 29.8% |
| 2013 FY | 1.26 Billion CNY | 57.44% |
| 2013 Q1 | 208.54 Million CNY | -13.96% |
| 2013 Q2 | 244.76 Million CNY | 17.37% |
| 2012 FY | 801.02 Million CNY | 30.02% |
| 2012 Q1 | 138.79 Million CNY | -32.91% |
| 2012 Q3 | 215.37 Million CNY | 5.33% |
| 2012 Q2 | 204.47 Million CNY | 47.32% |
| 2012 Q4 | 242.37 Million CNY | 12.54% |
| 2011 Q4 | 206.88 Million CNY | 14.89% |
| 2011 Q1 | 106.96 Million CNY | -37.51% |
| 2011 FY | 616.09 Million CNY | 20.01% |
| 2011 Q2 | 122.16 Million CNY | 14.21% |
| 2011 Q3 | 180.07 Million CNY | 47.4% |
| 2010 FY | 513.38 Million CNY | 35.59% |
| 2010 Q3 | 154.32 Million CNY | 50.8% |
| 2010 Q2 | 102.33 Million CNY | 19.65% |
| 2010 Q4 | 171.18 Million CNY | 10.93% |
| 2010 Q1 | 85.53 Million CNY | -24.18% |
| 2009 FY | 378.63 Million CNY | 28.43% |
| 2009 Q3 | 101.84 Million CNY | 0.0% |
| 2009 Q4 | 112.8 Million CNY | 10.77% |
| 2008 FY | 294.8 Million CNY | 14.13% |
| 2007 FY | 258.3 Million CNY | 0.0% |